Actavis PLC (ACT): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 1.8%. By the end of trading, Actavis fell $6.33 (-2.8%) to $220.82 on heavy volume. Throughout the day, 3,710,133 shares of Actavis exchanged hands as compared to its average daily volume of 2,017,300 shares. The stock ranged in price between $219.66-$227.71 after having opened the day at $227.71 as compared to the previous trading day's close of $227.15. Other companies within the Health Care sector that declined today were: Endologix ( ELGX), down 24.4%, Compugen ( CGEN), down 20.1%, Medivation ( MDVN), down 14.9% and Kindred Biosciences ( KIN), down 14.6%.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $39.6 billion and is part of the drugs industry. Shares are up 35.2% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

On the positive front, Flexion Therapeutics ( FLXN), up 11.8%, Cormedix ( CRMD), up 10.7%, Iridex Corporation ( IRIX), up 9.2% and Cara Therapeutics ( CARA), up 8.8% , were all gainers within the health care sector with Medtronic ( MDT) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Icahn Bets on Allergan's Brett Saunders in Post-Pfizer Era

What Bill Ackman's Voice Could Mean for the Valeant Board Room

What Bill Ackman's Voice Could Mean for the Valeant Board Room

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Federal Reserve to Reassess Global Risks in Minutes on Wednesday

Can Allergan-Pfizer Survive Treasury's New Crackdown on Inversions?